ProstaLund AB
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow, a temporary prostate stent; Oruflow, a urine flow meter; and Schelin Catheter, a medical device intended for intraprostatic and periprostatic injection of legally mark… Read more
ProstaLund AB (PLUN) - Net Assets
Latest net assets as of June 2025: Skr44.54 Million SEK
Based on the latest financial reports, ProstaLund AB (PLUN) has net assets worth Skr44.54 Million SEK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr55.84 Million) and total liabilities (Skr11.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr44.54 Million |
| % of Total Assets | 79.76% |
| Annual Growth Rate | 22.8% |
| 5-Year Change | 117.66% |
| 10-Year Change | 137.92% |
| Growth Volatility | 46.65 |
ProstaLund AB - Net Assets Trend (2012–2024)
This chart illustrates how ProstaLund AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ProstaLund AB (2012–2024)
The table below shows the annual net assets of ProstaLund AB from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr55.18 Million | -0.20% |
| 2023-12-31 | Skr55.29 Million | +32.64% |
| 2022-12-31 | Skr41.69 Million | +17.57% |
| 2021-12-31 | Skr35.46 Million | +39.85% |
| 2020-12-31 | Skr25.35 Million | +14.03% |
| 2019-12-31 | Skr22.23 Million | +74.90% |
| 2018-12-31 | Skr12.71 Million | -7.72% |
| 2017-12-31 | Skr13.78 Million | -55.29% |
| 2016-12-31 | Skr30.81 Million | +32.85% |
| 2015-12-31 | Skr23.19 Million | +95.13% |
| 2014-12-31 | Skr11.89 Million | +127.09% |
| 2013-12-31 | Skr5.23 Million | +11.58% |
| 2012-12-31 | Skr4.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ProstaLund AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3562300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr14.50 Million | 26.27% |
| Other Comprehensive Income | Skr32.25 Million | 58.45% |
| Other Components | Skr44.62 Million | 80.85% |
| Total Equity | Skr55.18 Million | 100.00% |
ProstaLund AB Competitors by Market Cap
The table below lists competitors of ProstaLund AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
72GU
LSE:72GU
|
$576.81K |
|
BIJBF
OTCGREY:BIJBF
|
$576.92K |
|
Transpaco Ltd
JSE:TPC
|
$577.01K |
|
CYMBRIA CORP. CLASS A
F:CYOA
|
$577.58K |
|
THE BITCOIN FUND UTS A
F:7T9
|
$576.45K |
|
nDatalyze Corp
OTCQB:NDATF
|
$576.33K |
|
ATLANTICUS HLDGS
BE:YCC
|
$575.82K |
|
SURFACE TRANSF PLC LS-01
F:XE4
|
$575.50K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ProstaLund AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 55,291,000 to 55,181,000, a change of -110,000 (-0.2%).
- Net loss of 22,631,000 reduced equity.
- New share issuances of 26,952,000 increased equity.
- Other comprehensive income increased equity by 33,395,999.
- Other factors decreased equity by 37,826,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-22.63 Million | -41.01% |
| Share Issuances | Skr26.95 Million | +48.84% |
| Other Comprehensive Income | Skr33.40 Million | +60.52% |
| Other Changes | Skr-37.83 Million | -68.55% |
| Total Change | Skr- | -0.20% |
Book Value vs Market Value Analysis
This analysis compares ProstaLund AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.16x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.89 | Skr0.21 | x |
| 2013-12-31 | Skr0.99 | Skr0.21 | x |
| 2014-12-31 | Skr1.62 | Skr0.21 | x |
| 2015-12-31 | Skr2.55 | Skr0.21 | x |
| 2016-12-31 | Skr2.42 | Skr0.21 | x |
| 2017-12-31 | Skr1.08 | Skr0.21 | x |
| 2018-12-31 | Skr0.90 | Skr0.21 | x |
| 2019-12-31 | Skr0.89 | Skr0.21 | x |
| 2020-12-31 | Skr0.66 | Skr0.21 | x |
| 2021-12-31 | Skr0.74 | Skr0.21 | x |
| 2022-12-31 | Skr0.77 | Skr0.21 | x |
| 2023-12-31 | Skr0.81 | Skr0.21 | x |
| 2024-12-31 | Skr1.38 | Skr0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ProstaLund AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -41.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -164.89%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.12x
- Recent ROE (-41.01%) is above the historical average (-52.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -11.96% | -7.33% | 1.11x | 1.47x | Skr-1.03 Million |
| 2013 | -88.75% | -53.92% | 0.90x | 1.84x | Skr-5.17 Million |
| 2014 | -65.51% | -80.99% | 0.61x | 1.33x | Skr-8.97 Million |
| 2015 | -40.41% | -68.85% | 0.50x | 1.17x | Skr-11.69 Million |
| 2016 | -38.86% | -81.95% | 0.41x | 1.14x | Skr-15.06 Million |
| 2017 | -122.65% | -124.73% | 0.76x | 1.30x | Skr-18.27 Million |
| 2018 | -101.88% | -95.45% | 0.71x | 1.51x | Skr-14.22 Million |
| 2019 | -48.25% | -83.25% | 0.49x | 1.19x | Skr-12.95 Million |
| 2020 | -39.61% | -80.55% | 0.40x | 1.22x | Skr-12.58 Million |
| 2021 | -22.33% | -46.38% | 0.39x | 1.23x | Skr-11.46 Million |
| 2022 | -27.11% | -64.92% | 0.34x | 1.22x | Skr-15.47 Million |
| 2023 | -30.76% | -76.60% | 0.34x | 1.18x | Skr-22.54 Million |
| 2024 | -41.01% | -164.89% | 0.22x | 1.12x | Skr-28.15 Million |
Industry Comparison
This section compares ProstaLund AB's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $3,735,333,333
- Average return on equity (ROE) among peers: 7.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ProstaLund AB (PLUN) | Skr44.54 Million | -11.96% | 0.25x | $576.77K |
| Ambea AB (AMBEA) | $4.68 Billion | 7.82% | 2.82x | $848.23 Million |
| Attendo AB (publ) (ATT) | $4.22 Billion | 6.78% | 1.20x | $933.99 Million |
| Humana AB (publ) (HUM) | $2.31 Billion | 8.15% | 2.57x | $110.09 Million |